Core Viewpoint - Merge Labs, a brain-computer interface project, has attracted interest from Sam Altman, who may participate as a co-founder, aiming to raise $250 million at an $850 million valuation, with significant funding expected from OpenAI Ventures [3]. Group 1: Project Overview - Merge Labs is exploring gene therapy to modify brain cells, aiming to create superior implantable devices, contrasting with Neuralink's approach [5]. - The project is in its early stages, with various ideas and technologies being considered, including the combination of gene therapy and ultrasound devices for monitoring and regulating modified cells [6][12]. Group 2: Competitive Landscape - If Altman enters the brain-computer interface space through Merge Labs, he will compete with Elon Musk's Neuralink, which is developing brain implants for disease treatment and human enhancement [7]. - Current implantable devices have already enabled paralyzed patients to control electronic devices and helped non-verbal individuals communicate [8]. Group 3: Scientific Background - The scientific community has been researching how to make cells responsive to ultrasound through gene modification, a field known as sonogenetics [9]. - Ultrasound has gained attention for its potential therapeutic applications in brain treatment, with some companies exploring non-invasive ultrasound devices for mental health issues [10][11].